Hot Long Term Companies To Watch For 2017

Related Solar Stocks Are Getting Killed By SolarCity's Whiff How One Interview Moved Sunedison Down 30% Solar stocks hammered again; SunEdison tumbles after lawsuit (Seeking Alpha) Related SolarCity Unable To Recover From Wednesday's Rout Barclays Downgrades SolarCity And Sunrun, Says Supreme Court And Weak Guidance Are Headwinds Tesla: Still Troubled By Model X Woes (Seeking Alpha)

Sunedison Inc (NYSE: SUNE) shares are flirting with the $2 area two days after SolarCity Corp (NASDAQ: SCTY) issued a disappointing outlook. The stock is down 14 percent on Thursday, on the back of further solar weakness instilled by Barclays' downgrade of SolarCity and Sunrun Inc (NASDAQ: RUN) before the market open.

Though the Barclays report didn't specifically mention Sunedison, it did warn that a slowdown in installations, rising funding costs and a potential CPP delay may slow investor bullishness in the space.

Hot Long Term Companies To Watch For 2017: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t h e treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By Johanna Bennett]

    The earnings season for Big Biotech kicks of later this month when Biogen (BIIB) unveils second quarter financial results on July 21. But will those reports be enough to reverse the negative sentiment surrounding the sector?

    The biotech analyst team at Cowen expects strong earnings driven by ,solid demand, an open pricing environment in the U.S. and a currency tailwind. But, they warn, the sector may lack sizzle.

    Steady financial performance in the absence of an exciting new product cycle may not be enough to overcome negative sentiment toward the groupInvestors are increasingly of the view that biotech fundamentals have deteriorated. They cite disappointing drug launches, a lack of pipeline catalysts, heightened payor pressures, and earnings growth that appears more dependent on financial engineering. While we admit that biotech is lacking an exciting new product cycle, we are not aware of any changes to the drug development process or commercial landscape that could have altered the industry’s fundamental value proposition. Rather we suspect that poor stock performance and investor sentiment may be engendering a “glass half empty” view toward fundamentals that are largely unchanged relative to a year ago when investors were touting biotech for its innovation cycle and increased R&D productivity. Earnings are the most objective metric for gauging perfor mance, and we expect Q2 to support the notion that biotech’s growth outlook and value proposition remain favorable relative to other sectors. As such, Q2 should provide the sector with a firmer level of support. However, more substantial upside is likely to be dependent on a change in sentiment, which is subjective and always difficult to predict in terms of timing.

    Which names are the best plays?

    According to Cowen, names with the potential to report Q2 results in excess of consensus include Acorda Therapeutics (ACOR), Alexion (ALXN), Biogen,

Hot Long Term Companies To Watch For 2017: Clarke(t)

T.Clarke plc, a building services contractor, provides electrical and mechanical installation services and supplies associated equipment. The company offers information communications technology (ICT) services in the areas of structured cabling and connectivity, network infrastructure and security, networked energy management, data centre infrastructure, and managed and support services; facilities management services, such as preventative, reactive, and planned maintenance solutions; and green technologies services, which comprise photovoltaics, rainwater harvesting, biomass boilers, ground source heating, air source heating, wind turbines, lighting, and carbon reduction audit services. It also provides massive reading station redevelopment, cross rail, border rail link, and underground power upgrade services for the rail sector; lifecycle building services combining mechanical and electrical works with ICT for utilities and technologies sectors; lifecycle services for ho tel and residential sectors, which include electrical, ICT, and mechanical systems design, installation, commissioning, and maintenance; and mechanical and electrical contracting services for education, healthcare, government/local authority, retail and leisure, stadiums, transport, towers, media, and residential sectors. In addition, the company manufactures and prefabricates elements of an installation, as well as engineering components. T.Clarke plc was founded in 1889 and is headquartered in London, the United Kingdom.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    24/7 Wall St. believes that AT&T Inc. (NYSE: T), General Electric Co. (NYSE: GE), Goldman Sachs Group Inc. (NYSE: GS), J.P. Morgan Chase & Co. (NYSE: JPM), Nike Inc. (NYSE: NKE) and Walt Disney Co. (NYSE: DIS) will all make dividend hike announcements before the end of 2013.

10 Best Canadian Stocks To Buy Right Now: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Reports suggest that Gilead Sciences (GILD) and Celgene (CELG) have joined the bidding process forMedivation (MDVN), one that already includes (maybe) Amgen (AMGN), and of course Sanofi (SNY), which is trying to throw out Medivation’s board. Of the three biotech giants, Citigroup’s Robyn Karnauskas and team argue that Amgen is best positioned to win the battle. They explain why:

  • [By Bioassociate Consulting]

    Focused on development and commercialization of products for the aesthetic medicine market, Kythera is led by a highly experienced management team, boasting impressive record in the pharmaceutical industry and the aesthetic medicine market, as former Allergan (AGN) and Amgen (AMGN) executives. Kythera has been flying under the radar since its October 2012 IPO, and the successful completion of the Phase III program is expected to bring KYTH to the front, and in our opinion, makes it a buyout target.

  • [By Craig Jones]

    On CNBC’s Options Action, Carter Worth analyzed Amgen, Inc. (NASDAQ: AMGN) from a technical standpoint.

    He said that the stock consistently outperformed iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which is in his opinion a basis for a bullish setup. Worth believes the stock is going to break out on the upside and reach its highs at $181.

Hot Long Term Companies To Watch For 2017: Intrepid Potash, Inc(IPI)

 

Intrepid Potash, Inc. engages in the extraction, production, and sale of potassium containing products in the United States. It produces muriate of potash and langbeinite, a low-chloride potassium fertilizer that contains sulfate and magnesium. The company also offers salt, magnesium chloride, and metal recovery salts. It serves agricultural, industrial, and animal feed markets. The company was incorporated in 2007 and is based in Denver, Colorado.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Gains are being seen elsewhere as well, except in shares of The Mosaic Company (NYSE: MOS). AgriumInc. (NYSE: AGU) was up almost 3% at $91.95 in late Monday trading, although this one held up much better in the destructive news phase when the alarming news roiled these stocks. The big winner is Intrepid Potash, Inc. (NYSE: IPI), with a gain of 7% to $16.20 in late-Monday trading.

Hot Long Term Companies To Watch For 2017: Spirit Airlines Inc.(SAVE)

Spirit Airlines, Inc. provides passenger airline services. It provides travel opportunities principally to and from south Florida, the northeast United States, the Caribbean, and Latin America. The company also offers optional travel-related products or services. As of December 31, 2011, it had a fleet of 37 Airbus single-aisle aircrafts. The company was formerly known as Charter One and changed its name to Spirit Airlines, Inc. in 1992. Spirit Airlines, Inc. was founded in 1964 and is headquartered in Miramar, Florida.

Advisors’ Opinion:

  • [By Ben Levisohn]

    There were 67 times this happened, the first coming in June 2011 (airlines didnt guide to margins before that), and 66 of these instances came from Delta, United, andAmerican (the 67th wasSpirit Airlines (SAVE)). As we said earlier the most short term alpha, +5.3%, was generated over the subsequent four days by being long airlines into a guidance update where an airline would merely affirm a PRASM guide but raise the margin guide. This only happened four times and obviously was a result of airlines holding some semblance of price as costs declined.

  • [By Ben Levisohn]

    Yesterday, shares of United Continental (UAL) and American Airlines (AAL) got pummeled after Delta Air Lines (DAL) offered disappointing guidance. Today, airline stocks are getting smacked again, this time after Credit Suisse Julie Yates and Parker Kim cut their ratings on American and United Continental, while stating a preference for airlines like Southwest Airlines (LUV) and Spirit Airlines (SAVE) that have low exposure to international air travel. They explain why:

  • [By Ben Levisohn]

    Given YTD performance, everything looks cheap. But we remain selective. Ex-Spirit Airlines (SAVE), our entire coverage universe is down year-to-date, with most names also underperforming the S&P 500. Multiples have compressed, with diminishing differentiation between (for example) those with declining leverage (Delta) vs. those where leverage is on the rise (America). In a vacuum, a Buy could potentially be argued for any individual name. Based on estimated risk and upside potential, Delta and Southwest are our top two picks.

  • [By Ben Levisohn]

    Stifel’s Joseph DeNardi explains why United Continental’s (UAL) choice of formerAllegiant Travel (ALGT) President Andrew Levy is good news for Spirit Airlines (SAVE) and Allegiant:

Hot Long Term Companies To Watch For 2017: American International Group Inc.(AIG)

American International Group, Inc. is an international insurance organization. The company operates property and casualty insurance networks worldwide and conducts activities in the U.S. life insurance and retirement services industry. It also involves in commercial aircraft leasing and residential mortgage guaranty insurance businesses. The company, through Chartis Inc., provides various property and casualty insurance products under commercial and consumer categories worldwide. These products include surplus lines, executive liability/directors? and officers? liability, employment practices, excess casualty, and travel/assistance lines. American International Group, through SunAmerica Financial Group, offers a suite of life insurance and retirement products and services, including term life, universal life, accident and health, fixed and variable deferred annuities, fixed payout annuities, mutual funds, and financial planning products and services to individuals and grou ps in the United States. The company, through International Lease Finance Corporation, operates as an aircraft lessor that acquires commercial jet aircraft from various manufacturers and other parties, and leases those aircraft to airlines worldwide. It also sells aircraft from its fleet to other leasing companies, financial services companies, and airlines, as well as provides management services to third-party owners of aircraft portfolios. American International Group, through United Guaranty Corporation, issues residential mortgage guaranty insurance that covers mortgage lenders from the first loss for credit defaults on high loan-to-value conventional first-lien mortgages for the purchase or refinance of one- to four-family residences in the U.S. and internationally. The company was founded in 1967 and is based in New York, New York.

Advisors’ Opinion:

  • [By David Sterman]

    My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).